Industry News
Biotechnology Industry News

RedHill’s second-try COVID pill staves off hospitalization in phase 2
RedHill's second-try COVID pill staves off hospitalization in phase 2 klahucik Tue, 03/01/2022 - 11:42
RedHill’s 2nd try COVID pill staves off hospitalization in phase 2
RedHill's 2nd try COVID pill staves off hospitalization in phase 2 klahucik Tue, 03/01/2022 - 11:42
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer’s and depression prospect
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect ntaylor Tue, 03/01/2022 - 08:47
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward ntaylor Tue, 03/01/2022 - 08:05
UPDATE: Editas shares boosted as patent office rules in favor of Broad’s CRISPR patents, but the fight will continue
UPDATE: Editas shares boosted as patent office rules in favor of Broad's CRISPR patents, but the fight will continue aarmstrong Mon, 02/28/2022 - 19:49
Intellia now has the data for No. 1 unanswered gene editing question: Does it last?
Intellia now has the data for No. 1 unanswered gene editing question: Does it last? aarmstrong Mon, 02/28/2022 - 14:56
Gemini CEO out the door as 80% of staff laid off, strategic review gets underway
Gemini CEO out the door as 80% of staff laid off, strategic review gets underway klahucik Mon, 02/28/2022 - 11:28
FDA sticks a fork in Reata’s treatment for chronic kidney disease
FDA sticks a fork in Reata’s treatment for chronic kidney disease mbayer Mon, 02/28/2022 - 11:00
Amryt’s shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealed
Amryt's shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealed aarmstrong Mon, 02/28/2022 - 10:56
Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assets
Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assets klahucik Mon, 02/28/2022 - 10:35
Blueprint marks protein degrader path in $632M biobucks pact with a Vant
Blueprint marks protein degrader path in $632M biobucks pact with a Vant klahucik Mon, 02/28/2022 - 08:50
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy ntaylor Mon, 02/28/2022 - 06:37
Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signal
Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signal ntaylor Mon, 02/28/2022 - 05:41
Goldfinch’s phase 2 kidney disease therapy scores in one indication, misses in another
Goldfinch's phase 2 kidney disease therapy scores in one indication, misses in another mbayer Mon, 02/28/2022 - 02:20
Biohaven to take a chance on Bristol Myers’ once-failed DMD med
Biohaven to take a chance on Bristol Myers' once-failed DMD med mbayer Fri, 02/25/2022 - 10:50
MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successor
MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successor ntaylor Fri, 02/25/2022 - 06:39
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market ntaylor Fri, 02/25/2022 - 05:49
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharma
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharma klahucik Thu, 02/24/2022 - 14:51
UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion
UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion klahucik Thu, 02/24/2022 - 14:51
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020 klahucik Thu, 02/24/2022 - 12:46

